Horizon is now part of PerkinElmer, Inc.
As of 23 December 2020, Horizon Discovery Group plc became part of
PerkinElmer, Inc. marking the next exciting stage of our development.
We are leveraging our technological expertise to provide cell engineering tools and services to our customers in three key areas of the therapeutics ecosystem:
“With the changes we are implementing under our Investing for Growth strategy, Horizon is well positioned to capitalise on its market-leading position.”
Our purpose is to continue to be the world’s leader in designing and engineering genetically modified cells for research/clinical applications that advance human health.
We will do this by being a sustainably profitable business that is driven by customer demand for our market-leading products and services.

A strong and focused leadership team
Board members come from a broad range of backgrounds and have the depth of skills and experience needed to provide effective guidance to the executive leadership of Horizon as they drive the Group into its profitable growth phase.

Key strengths
Built upon decades of experience in the engineering of cell lines, we have created a unique and high value portfolio of tools and services that support and enable critical elements of the drug development and therapeutic value chain. We believe this expertise forms the basis of a sustainable competitive position.
Featured news
Please click here to see non-regulatory and general company news on Horizon’s main company web site.